Jefferies analyst Brian Tanquilut assumed coverage of National Vision with a Buy rating with a price target of $45, up from $40. Despite emerging macro-related concerns, the valuation looks "compelling" given the company’s growth outlook, said the analyst as he assumed coverage of a trio of outpatient consumer health names.
Published first on TheFly
